5-((6-fluoro-5-(1-methyl-1H-indol-5-yl)-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid | 1219739-55-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-((6-fluoro-5-(1-methyl-1H-indol-5-yl)-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid
• 英文别名: 5-[6-fluoro-5-(1-methyl-1H-indol-5-yl)-1H-benzoimidazol-2-yloxy]-2-methyl-benzoic acid；5-[[6-fluoro-5-(1-methylindol-5-yl)-1H-benzimidazol-2-yl]oxy]-2-methylbenzoic acid
• CAS: 1219739-55-5
• 化学式: C₂₄H₁₈FN₃O₃
• 分子量: 415.424
• InChiKey: JLTGDQUESPULAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  80.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
  申请人：BOOKSER BRETT C.

  公开号：US20100081643A1

  公开（公告）日：2010-04-01

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，并且在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病方面非常有用。本发明的化合物在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面非常有用。
• [EN] BENZIMIDAZOLE DIRECT AMPK ACTIVATORS<br/>[FR] BENZIMIDAZOLE ACTIVATEURS DIRECT DE L'AMPK
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2018035128A1

  公开（公告）日：2018-02-22

  Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure Formula (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3, R4, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.

  揭示了苯并咪唑化合物，以及其药物组合物和使用方法。其中一种实施方式是具有结构式（I）的化合物及其药用可接受的盐、前药和N-氧化物（以及其溶剂和水合物），其中R1、R2、R3、R4、Y和X如本文所述。在某些实施方式中，本文披露的化合物可以激活AMPK，并可用于通过激活AMPK途径治疗疾病。
• Direct AMPK activators
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US11174246B2

  公开（公告）日：2021-11-16

  Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3, R4, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.

  所公开的是苯并咪唑化合物及其药物组合物和使用方法。其中一种化合物具有如下结构 及其药学上可接受的盐、原药和 N-氧化物（及其溶解物和水合物），其中 R1、R2、R3、R4、Y 和 X 如本文所述。在某些实施方案中，本文公开的化合物可激活 AMPK，并可通过激活 AMPK 途径来治疗疾病。
• DIRECT AMPK ACTIVATORS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20180051006A1

  公开（公告）日：2018-02-22

  Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R 1 , R 2 , R 3 , R 4 , Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.
• US8394969B2
  申请人：——

  公开号：US8394969B2

  公开（公告）日：2013-03-12